top of page

A dispute over a common asthma drug leaves patients caught in the middle

he most common asthma inhaler for children was discontinued at the start of this year, forcing parents and pediatricians to scramble to switch to an alternative.  


But more than a month later, the situation has not improved, and families remain caught in the middle of a fight between a drug company and pharmacy benefit managers (PBMs) with no end in sight. 


Comments


bottom of page